Ceriello A, Marchi E, Palazzni E, Quatraro A, Giugliano D
Cattedra di Diabetologia e Dietoterapia, I Facoltà di Medicina, Universita di Napoli, Italy.
Diabete Metab. 1990 Mar-Apr;16(2):86-92.
Alteration of antithrombin III (ATIII) activity, glycemia level dependent, exists in diabetes mellitus. In this study the ability of a low molecular weight heparin (LMWH) (Fluxum, Alfa-Wassermann S.p.A., Bologna, Italy), as well as unfractioned héparin, to preserve ATIII activity from glucose-induced alterations, both in vitro and in vivo, is reported. The subcutaneous and intravenous LMWH and heparin administration increases basal depressed ATIII activity in diabetic patients. Heparin shows an equivalent effect on both anti-IIa and anti-Xa activity of ATIII, while LMWH is more effective in preserving the anti-Xa activity. Similarity, heparin preserves ATIII activity from hyperglycemia-induced alterations, during hyperglycemic clamp, and LMWH infusion is able to preserve a significant amount of anti-Xa activity from glucose-induced alterations. Since diabetic patients show a high incidence of thrombotic accidents, LMWH appears to be a promising innovation for the prevention of diabetic thrombophylia.
抗凝血酶III（ATIII）活性的改变存在于糖尿病中，且依赖于血糖水平。本研究报道了一种低分子量肝素（LMWH）（Fluxum，意大利博洛尼亚阿尔法 - 瓦塞尔曼股份公司）以及普通肝素在体外和体内保护ATIII活性免受葡萄糖诱导改变的能力。皮下和静脉注射LMWH及肝素可增加糖尿病患者基础降低的ATIII活性。肝素对ATIII的抗IIa和抗Xa活性显示出同等效果，而LMWH在保护抗Xa活性方面更有效。同样，在高血糖钳夹期间，肝素可保护ATIII活性免受高血糖诱导的改变，且输注LMWH能够保护大量抗Xa活性免受葡萄糖诱导的改变。由于糖尿病患者血栓形成事件的发生率较高，LMWH似乎是预防糖尿病血栓形成的一项有前景的创新。
